Sign In
Buy AKBA
$0.84
-0.0659 (-7.24%)
At Close: Aug 10, 2026
New Strong Sell Stocks for November 22nd
04:56am, Friday, 22'nd Nov 2024
ATI, AKBA and ALTG have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2024.
Q3 2024 Earnings: Hold Akebia Therapeutics
03:31pm, Wednesday, 20'th Nov 2024
Akebia Therapeutics, Inc.'s stock has surged nearly 35% after positive updates on its Vafseo (vadadustat) and promising third-quarter results, despite macroeconomic challenges. The company is expandin
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
08:00am, Thursday, 14'th Nov 2024
Akebia continues to publish important results of FO2CUS trial to further physicians' understanding of Vafseo® (vadadustat) CAMBRIDGE, Mass. , Nov. 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, In
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
08:00am, Tuesday, 12'th Nov 2024
CAMBRIDGE, Mass. , Nov. 12, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, t
Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript
01:59pm, Thursday, 07'th Nov 2024
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - Chief E
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
09:15am, Thursday, 07'th Nov 2024
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago.
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
07:00am, Thursday, 07'th Nov 2024
Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025 Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dial
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 01'st Nov 2024
CAMBRIDGE, Mass. , Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grant
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
08:00am, Friday, 01'st Nov 2024
Akebia to Host Conference Call on November 7, 2024, at 8:00 a.m. EST CAMBRIDGE, Mass.
Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U.S. dialysis centers CAMBRIDGE, Mass. , Oct. 22, 2024 /PRNewswire/ -- Akebia Thera
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
08:00am, Tuesday, 15'th Oct 2024
Vadadustat clinical data on display for nephrologist and healthcare providers in advance of U.S. market availability expected in January 2025 CAMBRIDGE, Mass. , Oct. 15, 2024 /PRNewswire/ -- Akebia Th
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
08:00am, Thursday, 10'th Oct 2024
Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate A HCPCS code has also been assig
U.S. Renal Care is a leading provider of in-center and home dialysis in the United States CAMBRIDGE, Mass. , Oct. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutica
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 01'st Oct 2024
CAMBRIDGE, Mass. , Oct. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, gran
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
08:00am, Thursday, 05'th Sep 2024
Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care Trial aims to build a body of real-world evidence to understand the poten
